J&J's Xarelto pads artery disease case by reducing amputation, death rates vs. aspirin

15th November 2017 Uncategorised 0

Johnson & Johnson is hoping Xarelto can win approval in peripheral and coronary artery disease patients after dropping positive data in August. Now, it has more results to back up its case—and help it extend its indication lead over the competition.

More: J&J's Xarelto pads artery disease case by reducing amputation, death rates vs. aspirin
Source: fierce